RAS is one of the most frequently mutated oncogenes in cancer with ~30% of all human tumors harboring a mutation in either HRAS, NRAS, or KRAS isoforms. Despite countless efforts for the development of small molecule inhibitors for RAS, it remains an elusive target in the clinic. Here I demonstrate...